EMA Authorised: Kisplyx (lenvatinib mesilate) — Eisai GmbH

View source ↗

Summary

The European Medicines Agency authorised Kisplyx (lenvatinib mesilate) by Eisai GmbH for renal cell carcinoma. The decision included accelerated assessment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Kisplyx (lenvatinib mesilate)

Snippet

Status: Authorised. Therapeutic area: Carcinoma, Renal Cell. MAH: Eisai GmbH. Decision date: 26/03/2026. Accelerated assessment